CXC chemokines, including human interleukin-8 and rat cytokine-induced neutrophil chemoattractant-1 (CINC-1), play a crucial role in the pathogenesis of intestinal inflammation induced by ischemia-reperfusion (I-R). Thrombin and its specific receptor, protease-activated receptor 1 (PAR1), act as important players in inflammation.
Introduction
Ischemia itself causes tissue damage, but further injury can occur when the blood flow to ischemic tissue is restored in an attempt to maintain cell function and viability (5, 23, 24) . Such ischemia-reperfusion (I-R) injury is one of the grave conditions resulting from small intestinal transplantation, abdominal aortic aneurysm, hemorrhagic, traumatic or septic shock, or severe burns (2, 11, 12) . According to previous studies (5, 14, 16, 32) , neutrophils and oxygen-derived free radicals created in the gastrointestinal mucosa via neutrophil-endothelial cell interactions are involved in the pathogenesis of intestinal I-R injury. It is well known that activated neutrophils can cause tissue damage by releasing cytotoxic free radicals (6, 11, 21) .
Thrombin, a multifunctional serine protease, plays a critical role in hemostasis, coagulation, and thrombosis. In addition, thrombin can function as an agonist for cellular responses in a variety of cell types. Thrombin is known to have inflammatory functions via G protein-coupled receptors, including protease-activated receptor-1 (PAR1) (3, 15) . It has been reported that PAR1 induces rat cytokine-induced neutrophil chemoattractant-1 (CINC-1), a CXC-chemokine of interleukin-8 family (7, 8) , release (30) and that thrombin stimulates pro-inflammatory production in vivo (31) , and in vitro (4, 20, 28) . However, the role of the thrombin/PAR1 pathway in intestinal I-R has not yet been investigated. In this study we examined whether thrombin and PAR1 might be involved in the pathophysiology of intestinal I-R by administering antithrombin (AT), a specific inhibitor for thrombin, to rats treated with I-R. AT is a single-chain glycoprotein that binds to thrombin and a progressive inhibitor of serine proteases. It is the Page 4 of 32 5 physiological inhibitor of the central enzyme of blood coagulation (26) . It is well known that in the presence of heparin, which binds to AT, the rates of inactivation of thrombin and the other coagulation enzymes are accelerated (25). Besides anti-coagulation effect, recent experimental studies have revealed that AT had anti-inflammatory effects in models of E. coli colitis (29) , endotoxin-induced hypotension (13) , and pulmonary vascular injury (22) . However, the effects of AT on intestinal I-R injury have not yet been studied. In this study, we showed that I-R increased the thrombin activation and the PAR1 expression, and that AT dramatically attenuated the I-R-induced intestinal injury and inflammation.
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Materials and Methods
Reagents
AT was kindly provided from Benesis Co. (Osaka, Japan). Enzyme-linked immunosorbent assay (ELISA) kits for rat tumor necrosis factor-(TNF-) and cytokine-induced neutrophil chemoattractant-1 (CINC-1) were obtained from BioSource International (Camarillo, CA) and Immuno-Biological Laboratories Co., Ltd.
(Gunma, Japan), respectively. All other chemicals used were of reagent grade.
Preparation of rats for intestinal I-R
Male Wistar rats weighing 180-200 g were obtained from Keari Co., Ltd. (Osaka, Japan). The animals were housed at 22˚C in a controlled environment with 12 h of artificial light per day. The animals were not fed for 24 h prior to the experiments, but were allowed free access to water. Through a midline abdominal incision, intestinal I-R injury was induced by clamping the superior mesenteric artery (SMA) for 30 min under intraperitoneal urethane anesthesia (1,000 mg/kg) in rats with and without AT treatment.
After 30 min of occlusion, reperfusion was produced by removing the clamp. At 60 min after reperfusion, all of the rats were sacrificed by exsanguination via the abdominal aorta under intraperitoneal urethane anesthesia (1,000 mg/kg) for histological examination, biochemical studies, and RNA analysis. AT was administered to rats by 
Measurement of Thrombin-antithrombin complex (TAT)
Blood samples were collected via the inferior vena cava under intraperitoneal urethane anesthesia at four given time points (before and 30 min after ischemia, and 30 min and 60 min after reperfusion) and centrifuged at 1500 rpm for 5 min at 4˚C to obtain plasma samples. Briefly, 50 µl of plasma was placed into 96-well plates coated with rabbit anti-thrombin antibody and incubated for 15 min at 37˚C. Then the supernatants were removed, and the wells were washed with 1% bovine serum albumin and 0.05% Tween-20 in phosphate-buffered saline (PBS). Subsequently, horseradish peroxidase-conjugated rabbit-anti human AT antibody was added, and the amount of TAT was determined colorimetrically 30 min later (492-nm wavelength; MPR-A4i microplate reader; Tosoh, Tokyo, Japan) using tetra methyl benzidine as a substrate.
Assessment of intestinal mucosal injury induced by I-R
The animals were sacrificed after reperfusion, and the intestine was removed and submitted for examination. A distal segment of the ileum (30 cm) was excised from a region 5 cm proximal to the terminal ileum and submitted to measurement of luminal protein and hemoglobin. Saline (10 mL) was injected into the intestinal loop from oral side to collect the luminal contents from the other side. Then the protein and hemoglobin levels in the intestinal lumen were measured for evaluation of intestinal injury. The hemoglobin level, which reflects intestinal bleeding, was measured using a kit (Wako Pure Chemical Industries Ltd., Osaka, Japan) and the protein concentration was also measured by the Lowry method using commercially available kit (Bio-Rad Laboratories, Hercules, CA, USA) according to the manufacturer's protocol. A distal segment of the ileum (10 cm) was excised from a region 5 cm proximal to the terminal ileum and submitted to histological examination and measurement of biochemical parameters. For histological evaluation, formalin-fixed tissues were stained with hematoxylin and eosin and evaluated by light microscopy by a pathologist who was not informed of the experimental conditions for any given specimen. Subsequently, the intestinal mucosa was scraped off using two glass slides and homogenized in a homogenizer with 1.5 ml of 10 mM potassium phosphate buffer (pH 7.8) containing 30 mM KCL to measure tissue-associated myeloperoxidase (MPO) activity, and the levels of the inflammatory cytokines. Tissue-associated MPO activity, an index of neutrophil infiltration, was determined by a modification of the method described by Grisham et al. (6) . The MPO activity was assessed by measuring the H 2 O 2 -dependent oxidation of 3,3',5,5'-tetramethylbenzidine. One unit of enzyme activity was defined as the amount of MPO present that caused a change in absorbance of 1.0/min at 655 nm and 25˚C.
Determination of the mucosal content of TNF-and CINC-1
The concentrations of the inflammatory cytokines TNF-and CINC-1 in the supernatant of mucosal homogenates were determined by rat TNF-and CINC-1-specific ELISA kits according to the manufacturer's instructions. Briefly, 100 µl of cell supernatants were placed into 96-well plates coated with rabbit anti-rat GRO/CINC-1 IgG or TNF-IgG and incubated for 1 h at room temperature. Following this, the supernatants were removed, and the wells were washed with 1% bovine serum albumin and 0.05% Tween-20 in phosphate-buffered saline (PBS). Subsequently, horseradish peroxidase-conjugated rabbit-anti rat GRO/CINC-1 or TNF-antibody (Fab' fragments) was added, and the amount of CINC-1 or TNF-was determined colorimetrically 30 min later (490-nm wavelength; MPR-A4i microplate reader; Tosoh, Tokyo, Japan) using tetra methyl benzidine as a substrate.
RNA analysis
The mRNA expression of intestinal PAR1 was determined by real-time PCR, and those of intestinal TNF-and CINC-1 were determined by reverse transcription-polymerase chain reaction (RT-PCR) at 60 min after reperfusion. For both methods, total RNA was isolated from intestinal mucosal tissue by the acid guanidinium phenol chloroform method with an ISOGEN kit (Nippon Gene, Tokyo, Japan) and the concentration of RNA was determined by the absorbance at 260 nm in relation to that at 280 nm. The isolated RNA was stored at 70˚C until it was used for the real-time PCR and the RT-PCR. One microgram (1 µg) of extracted RNA was reverse-transcribed into first-strand complementary DNA (cDNA) at 42˚C for 40 min, using 100 U/ml of reverse-transcriptase (Takara Biomedicals, Shiga, Japan) and 0.1 µM of oligo (dT)-adapter primer (Takara Biomedicals) in a 50 µl reaction mixture.
Real-time PCR for PAR1 was carried out with a 7300 Real-Time PCR system 
Statistical analysis
All results were expressed as the mean ± SEM. The data were compared by two-way analysis of variance (ANOVA), and differences were considered to be significant if the P value was less than 0.05 based on Scheffe's multiple comparison test. All analyses were performed using the Stat View 5.0-J program (Abacus Concepts, Inc., Berkeley, CA, USA).
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Results
Reperfusion increased thrombin activity and PAR1 expression
Thrombin activation was assessed by measuring the TAT complexes. The serum level of TAT complexes was significantly increased after 30 min of ischemia, compared with that in the sham group, and this increase in the level of TAT complexes was further enhanced at 60 min after reperfusion (Fig.1) . Reperfusion also significantly enhanced the expression of PAR1 in the intestinal mucosa (Fig.2) .
AT inhibited intestinal I-R injury
Reperfusion after 30 min of ischemia resulted in an increase of the luminal protein and hemoglobin concentrations at 60 min after reperfusion (Fig. 3) . In contrast, treatment with AT at 5 min before ischemia inhibited the increase of luminal protein and hemoglobin at a dose of 30 U/kg, and there was no significant difference between sham and AT group (Fig. 3) . Neither vehicle alone nor AT alone affected the luminal protein and hemoglobin concentrations (data not shown). Therefore, in the following experiments, we used AT at a dose of 30 U/kg and examined its pharmacological action.
In the control group (I-R group), multiple erosions and bleeding were observed macroscopically after I-R injury, while these changes were inhibited by treatment with AT. The protective effect of AT was further confirmed microscopically. Representative hematoxylin and eosin-stained sections of the ileum from sham, I-R, and I-R plus AT-treated animals are depicted in Figure 4 . We found that the characteristic histological findings after I-R injury, shortening of the villi, loss of the villous epithelium (erosion), Page 12 of 32 13 and prominent mucosal neutrophil infiltration, while the ileum of sham animals exhibited normal mucosal architecture with intact villi. In contrast, administration of AT markedly inhibited these changes caused by I-R. AT alone did not produce any macroscopic or microscopic lesions in the rat intestine (data not shown).
Effect of AT on mucosal MPO activity
In the intestinal mucosa exposed to I-R injury, MPO activity was significantly increased compared with that in the sham group. This increase of MPO activity after reperfusion was significantly inhibited by treatment with AT (Fig. 5) .
Effect of AT on mucosal cytokine levels
The CINC-1 and TNF-levels in mucosal homogenate were increased significantly in the I-R group compared with those in the sham group. AT markedly reduced both the CINC-1 and TNF-concentrations compared with those in the I-R group (Fig. 6,7) .
Effect of AT on the expression of CINC-1 and TNF-mRNA
The expressions of CINC-1 and TNF-mRNA in the intestine were up-regulated by I-R injury. These increases in the expressions of CINC-1 and TNF-mRNA were also inhibited by AT (Fig. 8) .
Discussion
In the present study, we demonstrated that the serum level of TAT complexes, an index of thrombin activation, and the intestinal mRNA level of PAR1, a specific receptor of thrombin, were both increased after intestinal I-R, and that the treatment with AT, a synthetic thrombin inhibitor, markedly ameliorated the intestinal injury and inflammation induced by I-R in rats. These data suggest that the signaling pathway as reflected by increases in TAT complex levels. More interestingly, the intestinal mRNA expression of PAR1 was increased after I-R in the present study. These data suggest that enhanced activation of the thrombin/PAR1 pathway plays a key role in the pathogenesis of I-R-induced intestinal injury. In our study, the concentration of TAT was decreased at 60 min and significantly increased at 90min, which might indicate that TAT complexes were activated again during 60 min after ischemia.
In order to clarify the role of thrombin in the present study, we investigated the effect of AT, a synthetic thrombin inhibitor, on I-R-induced intestinal injury and inflammation. In this study, intestinal injury was assessed by a variety of methods, including the measurement of luminal concentrations of protein and hemoglobin, and histological findings. The result of each assessment showed that AT administration significantly inhibited these parameters. In addition, we demonstrated that AT significantly inhibited the expression of pro-inflammatory cytokines (CINC-1 and TNF-) and neutrophil accumulation determined by MPO activity in the intestine after I-R. These results indicate that AT has a protective role against I-R-induced intestinal mucosal injury as well as an anti-inflammatory role against I-R-induced inflammation.
The protection against I-R injury by AT has been supported by several studies, in which AT treatment ameliorated the renal and hepatic injury induced by I-R (9, 18). While previous reports using in vivo models have shown that AT exerts an anti-inflammatory effect at high dose such as 250 U/kg, in the present study we found that AT even at low-dose (30 U/kg) was effective to protect intestinal mucosa from I-R injury. Although the reason of discrepancy between their and our results is not clear and should be further investigated, the amount of AT used in this study is similar to that used in the clinical field (1). Taken together, these results suggest AT may exert a therapeutic effect on tissue ischemia and diseases related to I-R.
To examine the mechanism of cytoprotection by AT, we measured several biochemical parameters in the present study. The intestinal tissue levels of CINC-1, TNF-, and MPO were significantly increased after I-R in rats, and these variables reflecting leukocyte activation were significantly reduced by administering AT, suggesting that AT might reduce the intestinal injury by inhibiting leukocyte activation. through activation of cyclooxygenase in rats. However, in a study using the same rat model, we previously reported that inhibitors of cyclooxygenase 1 or 2 did not affect the severity of intestinal injury induced by I-R (19). Our preliminary experiment supports a direct action of AT in a "thrombin-independent" manner on activated endothelial cells, in which pro-inflammatory cytokine IL-8 production by activated human umbilical venous endothelial cells is inhibited by pretreatment with AT (unpublished data).
Therefore we speculated that the anti-inflammatory effect of AT is dependent not only on its indirect effect by inhibiting thrombin pathway but also on its direct effect by modulating intracellular signaling in intestinal model of I-R. Further studies will be 
